Media headlines about Catalyst Pharmaceuticals (NASDAQ:CPRX) have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Catalyst Pharmaceuticals earned a daily sentiment score of 0.04 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.93646537886 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:

A number of brokerages have recently weighed in on CPRX. Piper Jaffray Companies set a $6.00 price objective on shares of Catalyst Pharmaceuticals and gave the company a “buy” rating in a report on Monday. Zacks Investment Research lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th.

Shares of Catalyst Pharmaceuticals (CPRX) opened at 2.89 on Tuesday. The firm’s market capitalization is $242.14 million. The stock has a 50 day moving average of $2.80 and a 200-day moving average of $1.91. Catalyst Pharmaceuticals has a one year low of $0.73 and a one year high of $3.20.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.06). On average, equities analysts anticipate that Catalyst Pharmaceuticals will post ($0.26) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/08/08/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-catalyst-pharmaceuticals-nasdaqcprx-share-price.html.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Insider Buying and Selling by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.